



**Corp. Off.:-** 201, "The Summit Business Bay"  
Behind Guru Nanak Petrol Pump,  
Off Andheri Kurla Road, Andheri (E),  
Mumbai - 400 093 (India)  
Ph. : +91 22 69073100

6<sup>th</sup> February 2026

**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400001  
Scrip Code: **533543**

**National Stock Exchange of India Ltd.**

Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai-400051  
Symbol: **BROOKS**

**Sub: Outcome of Board Meeting held on Friday, 6<sup>th</sup> February 2026.**

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 and Regulation 33, and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we hereby inform you that the Board of Directors of the Company, at its meeting held today, i.e., Friday, 6<sup>th</sup> February 2026, which commenced at 4:00 PM. and concluded at 7:45 PM., inter alia, considered, approved, and took on record the following:

1. The Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31<sup>st</sup> December 2025, along with the Limited Review Reports issued thereon by the Statutory Auditors of the Company.
2. The Special Resolution passed by the Members of the Company at the Annual General Meeting held on 26<sup>th</sup> September 2025 for alteration of the Object Clause of the Memorandum of Association has not taken effect, as Form MGT-14 filed with the Registrar of Companies was not approved. Accordingly, the existing Object Clause of the Memorandum of Association of the Company continues to remain in force.

The Financial Results will be published in the newspapers in terms of Regulation 47(1)(b) of SEBI Listing Regulations in due course.

The above information will also be available on the Company's website [www.brookslabs.net](http://www.brookslabs.net).



**Corp. Off.:-** 201, "The Summit Business Bay"  
Behind Guru Nanak Petrol Pump,  
Off Andheri Kurla Road, Andheri (E),  
Mumbai - 400 093 (India)  
Ph. : +91 22 69073100

We request you to kindly take the same on record.

Thanking You,

Yours faithfully,

For **BROOKS LABORATORIES LIMITED**

**Krutika Rane**

**Company Secretary and Compliance Officer**

**Membership no: 66310**

Encl.: As Stated

**Independent Auditor's Limited Review Report on Unaudited Standalone Financial Results of Brooks Laboratories Limited for the quarter ended December 31, 2025 and year to date results for the period from April 01, 2025 to December 31, 2025, pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To,  
The Board of Directors  
Brooks Laboratories Limited**

1. We have reviewed the accompanying Statement of Unaudited Standalone Ind AS Financial Results of Brooks Laboratories Limited ('the Company') for the quarter ended December 31, 2025 and year to date results for the period from April 01, 2025 to December 31, 2025 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation').
2. This Statement, which is the responsibility of the Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether standalone financial results are free of material misstatements. A review consists of making inquiries, primarily of people responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement

principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For D M K H & Co**

Chartered Accountants

**Firm's Registration No. 116886W**

MALAVIKA  
LOKESHWAR  
R

Digitally signed by  
MALAVIKA LOKESHWAR  
Date: 2026.02.06  
19:53:54 +05'30'

**CA Malavika Lokeshwar**

Partner

**Mem. No. 108628**

**UDIN: 26108628SFJFFG6880**

Place: Mumbai

Date: 06<sup>th</sup> February 2026

**Independent Auditor's Limited Review Report on Unaudited Consolidated financial results of Brooks Laboratories Limited for the quarter ended on December 31, 2025 and year to date results for the period from April 01, 2025 to December 31, 2025 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To,  
The Board of Directors  
Brooks Laboratories Limited**

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of Brooks Laboratories Limited ('the Holding Company') and its Jointly controlled entity for the quarter ended December 31, 2025 and year to date results for the period from April 01, 2025 to December 31, 2025 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review consists of making inquiries, primarily of people responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Brooks Steriscience Limited	Jointly Controlled Entity

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

### Other Matters

6. We did not review the financial results of the Jointly Controlled Entity vis Brooks Steriscience Limited included in the consolidated unaudited financial results, whose financial result includes the Group's share of net profit of Rs. 519.60 Lakhs and 1786.98 Lakh for the quarter ended December 31, 2025 and year to date results for the period from April 01, 2025 to December 31, 2025 respectively as considered in the consolidated unaudited financial results. These financial results have been reviewed by other auditor whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these Jointly controlled entity, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.
7. The Consolidated statement includes comparative figures of the Company for the quarter ended December 31, 2024

Our opinion is not qualified on above mentioned matters.

**For D M K H & Co**

Chartered Accountants

**Firm's Registration No. 116886W**

**MALAVIKA**  
**LOKESHWAR**

Digitally signed by  
MALAVIKA LOKESHWAR  
Date: 2026.02.06  
19:54:32 +05'30'

**CA Malavika Lokeshwar**

Partner

**Mem. No. 108628**

**UDIN: 26108628SUIBWI7825**

Place: Mumbai

Date: 06<sup>th</sup> February 2026

**Brooks Laboratories Limited**

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net | Website: www.brookslabs.net

**Statements of Unaudited Financial Results for the Quarter & Nine Months ended 31 December, 2025**

(Rs. In Lakhs)

Particulars	Standalone						Consolidated					
	Quarter Ended			Nine Months Ended		Year ended	Quarter Ended			Nine Months Ended		Year ended
	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
	Unaudited			Unaudited		Audited	Unaudited			Unaudited		Audited
<b>1 Income</b>												
Revenue from operations	1,656.63	2,345.07	2,051.51	6,552.89	5,924.01	8,255.68	1,656.63	2,345.07	2,051.51	6,552.89	5,924.01	8,255.68
Other Income	12.50	39.02	2.79	73.22	26.25	88.31	12.50	39.02	2.79	73.22	26.25	88.31
<b>Total income</b>	<b>1,669.13</b>	<b>2,384.09</b>	<b>2,054.30</b>	<b>6,626.11</b>	<b>5,950.26</b>	<b>8,343.99</b>	<b>1,669.13</b>	<b>2,384.09</b>	<b>2,054.30</b>	<b>6,626.11</b>	<b>5,950.26</b>	<b>8,343.99</b>
<b>2 Expenses</b>												
(a) Cost of materials consumed	908.03	1,042.00	1,216.82	3,311.65	3,336.81	4,704.40	908.03	1,042.00	1,216.82	3,311.65	3,336.81	4,704.40
(b) Purchase of Stock in Trade	149.24	300.14	118.57	690.14	545.28	717.69	149.24	300.14	118.57	690.14	545.28	717.69
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	(157.37)	29.01	(59.51)	(141.49)	(55.91)	(14.79)	(157.37)	29.01	(59.51)	(141.49)	(55.91)	(14.79)
(d) Employees benefits expenses	371.58	392.82	329.45	1,131.26	957.86	1,296.04	371.58	392.82	329.45	1,131.26	957.86	1,296.04
(e) Finance Costs	16.13	28.34	28.42	74.61	76.72	102.83	16.13	28.34	28.42	74.61	76.72	102.83
(f) Depreciation and amortization expenses	39.29	39.24	38.38	117.72	121.39	160.15	39.29	39.24	38.38	117.72	121.39	160.15
(g) Other expenses	311.95	328.81	288.52	923.15	800.12	1,054.91	311.95	328.81	288.52	923.15	800.12	1,054.91
<b>Total Expenses</b>	<b>1,638.85</b>	<b>2,160.36</b>	<b>1,960.65</b>	<b>6,107.04</b>	<b>5,782.27</b>	<b>8,021.23</b>	<b>1,638.85</b>	<b>2,160.36</b>	<b>1,960.65</b>	<b>6,107.04</b>	<b>5,782.27</b>	<b>8,024.77</b>
<b>3 Profit/(Loss) before Share of Profit / (Loss) of Associate, exceptional item and tax</b>	<b>30.28</b>	<b>223.73</b>	<b>93.65</b>	<b>519.07</b>	<b>167.99</b>	<b>322.76</b>	<b>30.28</b>	<b>223.73</b>	<b>93.65</b>	<b>519.07</b>	<b>167.99</b>	<b>319.22</b>
4 Share of Profit / (Loss) from Jointly controlled entities and associates	-	-	-	-	-	-	519.60	573.96	(306.87)	1,786.98	(1,018.89)	(1,298.38)
<b>Profit/(Loss) before Exceptional item and tax</b>	<b>30.28</b>	<b>223.73</b>	<b>93.65</b>	<b>519.07</b>	<b>167.99</b>	<b>322.76</b>	<b>549.88</b>	<b>797.69</b>	<b>(213.22)</b>	<b>2,306.05</b>	<b>(850.90)</b>	<b>(979.16)</b>
5 Exceptional items	-	-	-	-	-	-	-	-	-	-	-	-
<b>6 Profit/(Loss) from ordinary activities before tax</b>	<b>30.28</b>	<b>223.73</b>	<b>93.65</b>	<b>519.07</b>	<b>167.99</b>	<b>322.76</b>	<b>549.88</b>	<b>797.69</b>	<b>(213.22)</b>	<b>2,306.05</b>	<b>(850.90)</b>	<b>(979.16)</b>
<b>7 Tax Expense:</b>												
Deferred Tax Liability / (Assets)(Refer note 6)	-	-	-	-	-	-	-	-	-	-	-	-
MAT credit reversal	-	-	-	-	-	-	-	-	-	-	-	-
Tax of earlier years	-	-	-	-	-	17.54	-	-	-	-	-	17.54
<b>8 Net Profit/(loss) after tax</b>	<b>30.28</b>	<b>223.73</b>	<b>93.65</b>	<b>519.07</b>	<b>167.99</b>	<b>305.22</b>	<b>549.88</b>	<b>797.69</b>	<b>(213.22)</b>	<b>2,306.05</b>	<b>(850.90)</b>	<b>(996.70)</b>
<b>9 Other Comprehensive Income</b>												
Items That will not be reclassified into Profit or loss												
Actuarial Gain/ (Loss) on Defined Benefit Plans (Net of Tax)	-	-	-	-	-	(1.83)	-	-	-	-	-	(1.83)
<b>10 Total Comprehensive income for the period</b>	<b>30.28</b>	<b>223.73</b>	<b>93.65</b>	<b>519.07</b>	<b>167.99</b>	<b>303.39</b>	<b>549.88</b>	<b>797.69</b>	<b>(213.22)</b>	<b>2,306.05</b>	<b>(850.90)</b>	<b>(998.53)</b>
<b>Net Profit attributable to</b>												
Owners of equity	-	-	-	-	-	-	549.88	797.69	(213.22)	2,306.05	(850.90)	(996.70)
Non Controlling Interest	-	-	-	-	-	-	-	-	-	-	-	-
<b>Other Comprehensive Income attributable to :</b>												
Owners of equity	-	-	-	-	-	-	-	-	-	-	-	(1.83)
Non Controlling Interest	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total Comprehensive Income attributable to</b>												
Owners of Equity	-	-	-	-	-	-	549.88	797.69	(213.22)	2,306.05	(850.90)	(998.53)
Non Controlling Interest	-	-	-	-	-	-	-	-	-	-	-	-
<b>11 Paid-up equity share capital (Face Value of Rs. 10 each)</b>	<b>2,945.72</b>	<b>2,945.72</b>	<b>2,624.67</b>	<b>2,945.72</b>	<b>2,624.67</b>	<b>2,945.72</b>	<b>2,945.72</b>	<b>2,945.72</b>	<b>2,624.67</b>	<b>2,945.72</b>	<b>2,624.67</b>	<b>2,945.72</b>
<b>12 Reserves excluding Revaluation Reserves</b>						<b>8,561.25</b>						<b>6,864.71</b>
<b>13 Earnings per share (of Rs. 10/- each)</b>												
(not annualized)												
(a) Basic	0.10	0.76	0.36	1.76	0.64	1.14	1.87	2.71	(0.82)	7.83	(3.24)	(3.72)
(b) Diluted	0.10	0.76	0.36	1.76	0.64	1.14	1.87	2.71	(0.82)	7.83	(3.24)	(3.72)



**Notes:**


- 1 The above Financial Results of the Company have been reviewed by the Audit committee and approved by the Board of Directors at their respective meeting held on February 06, 2026.
- 2 The financial results have been prepared in accordance with Indian Accounting Standard ("Ind AS") prescribed under section 133 of the Companies Act 2013, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular Dated 5th July, 2016
- 3 During the previous year, the Company has issued 32,10,510 equity shares at issue price Rs 141.50 per share (having face value of Rs.10/- and premium of Rs.131.50 per share) on a preferential basis. Accordingly, the equity share capital of the Company increased from Rs. 2,624.67 Lakhs to Rs. 2,945.72 Lakhs post-issue.
- 4 Brooks Steriscience Limited, a jointly controlled entity, has recorded revenue from operations of Rs. 10,084.35 Lakhs for the Nine months ended 31 December, 2025, which includes licensing income & profit share of Rs. 5,211.35 Lakhs which have resulted in a profit after tax of Rs. 3,646.91 Lakhs. Accordingly, the share of the Company in profit after tax for the nine month ended 31 December, 2025 is Rs. 1,786.98 lakhs which has been reported above.
- 5 The Consolidated Financial Results have been prepared in accordance with Ind AS 110 on "Consolidated Financial Statements" and Ind AS 28 on "Investments in Associates and Joint Ventures".
- 6 In the absence of reasonable certainty of taxable profit, The Holding Company has not recognized deferred tax asset on its business losses/depreciation in accordance with Ind As 12 "Income taxes".
- 7 The Company operates through two reportable business segments in accordance with Ind AS 108 – Operating Segments, namely Trading and Manufacturing. Trading comprises principal-to-principal trading activities, while Manufacturing includes the Company's own manufacturing operations and loan-licensing business.
- 8 Prior period figures have been regrouped and reclassified where necessary.

For and on behalf of the Board



Bhushan Singh Rana  
Din : 10289384  
Whole time Director

Place : Baddi  
Date : 06/02/2026





**Brooks Laboratories Limited**

Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101

CIN NO: L24232HP2002PLC000267

E-mail : investors@brookslabs.net | Website: www.brookslabs.net


**Segment-wise Revenue, Results, Assets and Liabilities**

(Rs. In Lakhs)

Particulars	Standalone						Consolidated					
	Quarter Ended			Nine Months Ended		Year ended	Quarter Ended			Nine Months Ended		Year ended
	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
	Unaudited			Unaudited		Audited	Unaudited			Unaudited		Audited
<b>1 Segment Revenue</b>												
a) Trading	19.18	207.99	23.21	263.36	216.72	242.72	19.18	207.99	23.21	263.36	216.72	242.72
b) Manufacturing	1,637.45	2,137.08	2,028.30	6,289.53	5,707.29	8,012.96	1,637.45	2,137.08	2,028.30	6,289.53	5,707.29	8,012.96
	<b>1,656.63</b>	<b>2,345.07</b>	<b>2,051.51</b>	<b>6,552.89</b>	<b>5,924.01</b>	<b>8,255.68</b>	<b>1,656.63</b>	<b>2,345.07</b>	<b>2,051.51</b>	<b>6,552.89</b>	<b>5,924.01</b>	<b>8,255.68</b>
Less: Inter segment Revenue	-	-	-	-	-	-	-	-	-	-	-	-
	1,656.63	2,345.07	2,051.51	6,552.89	5,924.01	8,255.68	1,656.63	2,345.07	2,051.51	6,552.89	5,924.01	8,255.68
Add: Unallocated	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total revenue from operations</b>	<b>1,656.63</b>	<b>2,345.07</b>	<b>2,051.51</b>	<b>6,552.89</b>	<b>5,924.01</b>	<b>8,255.68</b>	<b>1,656.63</b>	<b>2,345.07</b>	<b>2,051.51</b>	<b>6,552.89</b>	<b>5,924.01</b>	<b>8,255.68</b>
<b>2 Segment Results</b>												
(a) Trading	(11.96)	31.44	(1.59)	5.30	9.48	10.08	(11.96)	31.44	(1.59)	5.30	9.48	10.08
(b) Manufacturing	66.48	227.03	131.50	606.11	257.23	441.58	66.48	227.03	131.50	606.11	257.23	441.58
<b>Total Segment results</b>	<b>54.52</b>	<b>258.47</b>	<b>129.91</b>	<b>611.41</b>	<b>266.71</b>	<b>451.66</b>	<b>54.52</b>	<b>258.47</b>	<b>129.91</b>	<b>611.41</b>	<b>266.71</b>	<b>451.66</b>
Less:												
(i) Finance costs	16.13	28.34	28.42	74.61	76.72	102.83	16.13	28.34	28.42	74.61	76.72	102.83
(ii) Other un-allocable (income) net of un-allocable expenditure	8.11	6.40	7.84	17.73	22.00	26.07	8.11	6.40	7.84	17.73	22.00	29.61
<b>Profit/(Loss) before Share of Profit / (Loss) of Associate, exceptional item and tax</b>	<b>30.28</b>	<b>223.73</b>	<b>93.65</b>	<b>519.07</b>	<b>167.99</b>	<b>322.76</b>	<b>30.28</b>	<b>223.73</b>	<b>93.65</b>	<b>519.07</b>	<b>167.99</b>	<b>319.22</b>
Share of Profit / (Loss) from Jointly controlled entities and associates	-	-	-	-	-	-	519.60	573.96	(306.87)	1,786.98	(1,018.89)	(1,298.38)
<b>Profit/(Loss) before Exceptional item and tax</b>	<b>30.28</b>	<b>223.73</b>	<b>93.65</b>	<b>519.07</b>	<b>167.99</b>	<b>322.76</b>	<b>549.88</b>	<b>797.69</b>	<b>(213.22)</b>	<b>2,306.05</b>	<b>(850.90)</b>	<b>(979.16)</b>
<b>3 Segment Assets</b>												
(a) Trading	137.48	207.37	122.96	137.48	122.96	71.17	137.48	207.37	122.96	137.48	122.96	71.17
(b) Manufacturing	5,186.01	5,058.75	5,081.74	5,186.01	5,081.74	4,818.01	5,186.01	5,058.75	5,081.74	5,186.01	5,081.74	4,818.01
<b>Total segment assets</b>	<b>5,323.49</b>	<b>5,266.12</b>	<b>5,204.70</b>	<b>5,323.49</b>	<b>5,204.70</b>	<b>4,889.18</b>	<b>5,323.49</b>	<b>5,266.12</b>	<b>5,204.70</b>	<b>5,323.49</b>	<b>5,204.70</b>	<b>4,889.18</b>
Add: Unallocated	9,135.11	9,157.85	4,787.55	9,135.11	4,787.55	9,176.78	9,225.55	8,728.69	3,768.66	9,225.55	3,768.66	7,480.24
<b>Total assets</b>	<b>14,458.60</b>	<b>14,423.97</b>	<b>9,992.25</b>	<b>14,458.60</b>	<b>9,992.25</b>	<b>14,065.96</b>	<b>14,549.04</b>	<b>13,994.81</b>	<b>8,973.36</b>	<b>14,549.04</b>	<b>8,973.36</b>	<b>12,369.42</b>
<b>4 Segment Liabilities</b>												
(a) Trading	122.12	180.05	113.48	122.12	113.48	61.11	122.12	180.05	113.48	122.12	113.48	61.11
(b) Manufacturing	2,310.44	2,248.16	2,757.63	2,310.44	2,757.63	2,497.88	2,310.44	2,248.16	2,757.63	2,310.44	2,757.63	2,497.88
<b>Total segment liabilities</b>	<b>2,432.56</b>	<b>2,428.21</b>	<b>2,871.11</b>	<b>2,432.56</b>	<b>2,871.11</b>	<b>2,558.99</b>	<b>2,432.56</b>	<b>2,428.21</b>	<b>2,871.11</b>	<b>2,432.56</b>	<b>2,871.11</b>	<b>2,558.99</b>
Add: Unallocated	-	-	-	-	-	-	-	-	-	-	-	-
<b>Total liabilities</b>	<b>2,432.56</b>	<b>2,428.21</b>	<b>2,871.11</b>	<b>2,432.56</b>	<b>2,871.11</b>	<b>2,558.99</b>	<b>2,432.56</b>	<b>2,428.21</b>	<b>2,871.11</b>	<b>2,432.56</b>	<b>2,871.11</b>	<b>2,558.99</b>

For and on behalf of the Board

Bhushan Singh Rana  
Din : 10289384  
Whole time Director



Place : Baddi  
Date : 06/02/2026